| Document |
Document Title |
|
WO/2024/101918A1 |
The present invention relates to a lipo-hydroxamic acid derivative and a pharmaceutical use thereof, the derivative being usefully employable as a composition for prevention, treatment, or reduction of eye disease by having been confirme...
|
|
WO/2024/101047A1 |
According to the present invention, a graft rejection reaction is reduced, and extracellular vesicles derived from cells having physiological activity against at least one disease among kidney diseases, peripheral arterial disease (PAD),...
|
|
WO/2024/098127A1 |
The present invention describes nanostructured lipid systems containing the antibiotic besifloxacin and the application thereof in the treatment and prevention of bacterial eye infections. Besifloxacin, an antibiotic with low aqueous sol...
|
|
WO/2024/100628A1 |
The present disclosure describes formulations and methods for hydrating dry eyes. The formulations comprise at least one natural humectant, at least one amino acid, and at least one vitamin, wherein the formulation is preservative free, ...
|
|
WO/2024/059819A3 |
The present disclosure relates to thin film preparations of cannabinoids (e.g., cannabidiol (CBD)) further comprising a magnesium stearate/menthol mixture in the preparation of dry powders used in administration by inhalation to and/or t...
|
|
WO/2024/099458A1 |
Disclosed in the present invention are a piperidine-substituted benzoic acid compound, and a pharmaceutical composition and the use thereof. The piperidine-substituted benzoic acid compound of the present invention is a compound as shown...
|
|
WO/2024/101859A1 |
The present invention relates to a sustained-release injectable preparation comprising dexamethasone acetate and a preparation method therefor.
|
|
WO/2024/101915A1 |
The present invention relates to a peptide nucleic acid complex having enhanced stability and improved inhibitory effects on a target gene, wherein the terminals of a bioactive peptide nucleic acid and a carrier peptide nucleic acid are ...
|
|
WO/2024/076993A3 |
Described herein are multi-specific antigen binding proteins that bind human fibrin or fibrinogen γC domain and vascular endothelial growth factor, and methods of use thereof. In certain aspects, described herein are pharmaceutical comp...
|
|
WO/2024/103000A1 |
Compositions, methods, and kits are provided for diagnosing and treating vestibular schwannoma. In particular, biomarkers associated with tumor growth and hearing loss have been identified that may be useful for diagnosing vestibular sch...
|
|
WO/2024/102798A1 |
Lipid nanoparticles that can be used as active molecule carriers for ophthalmic, dermatological, and/or cosmetic applications. The nanoparticles have an average particle size of less than 80 nm and a permeation enhancer that provides hig...
|
|
WO/2024/102346A1 |
This disclosure relates to methods of treating, e.g., eye pain and eye disorders, using dual N-type and L-type calcium channel blockers selective for the N-type calcium channel (e.g., cilnidipine).
|
|
WO/2024/102328A1 |
Methods are provided to prevent and to treat diabetic retinopathy by using Calcium channel blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors, angiotensin receptor blockers (ARB), or vasodilators, and more particularly, to a method...
|
|
WO/2024/101440A1 |
Provided is a compound represented by formula (1): [in the formula, the definitions for variables are as defined in the description] or a pharmaceutically acceptable salt thereof.
|
|
WO/2024/101434A1 |
This physiologically-active peptide derivative for the treatment of eye diseases comprises a physiologically-active peptide sequence and a functional sequence comprising a membrane permeation-promoting sequence and an endosomal escape-pr...
|
|
WO/2024/081352A3 |
The present disclosure provides third-generation self-inactivating (SIN) lentiviral vectors comprising a nucleic acid sequence encoding MyoVIIa isoform 1 for treatment of Usher IB syndrome in a subject in need thereof. In some embodiment...
|
|
WO/2024/102746A1 |
Methods are described for treating neurotrophic keratitis in a subject by administering an agent that inhibits fidgetin-like 2 activity, such as by using an RNA interference agent, e.g., siRNA.
|
|
WO/2024/099478A1 |
A selective inhibitor of PI3Kδ, and a free base, isomer, solvate, pharmaceutically acceptable salt and other structural forms thereof. The compounds have significant antagonistic activity on PI3Kδ, and a pharmacokinetic study shows tha...
|
|
WO/2024/097900A1 |
RNA molecules comprising a guide sequence portion having 17-50 contiguous nucleotides containing nucleotides in the sequence set forth in any one of SEQ ID NOs: 1-2325 and compositions, methods, and uses thereof.
|
|
WO/2024/095005A1 |
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts, N-oxides, solvates and prodrugs thereof: wherein V, W, X, Y, Z, A1, A2, A3, A4, A5, A6, A7, A8, A9 and R3 are as defined in the specification,...
|
|
WO/2024/095026A1 |
In the present invention azidation is used to render a molecule photoactivable and to influence its binding to its cognate specific binding partner in the eye. Thus, the invention relates to a compound for use in a method of treating a s...
|
|
WO/2024/094759A1 |
There is provided herein a composition comprising liposomes, which comprise a lipid component and a phospholipid component, which compositions are useful in the treatment of ocular surface disorders.
|
|
WO/2024/096629A1 |
The present invention provides an eye drop composition for treating, preventing, or ameliorating dry eye syndrome or a dry eye-related disease, the eye drop composition comprising a compound represented by chemical formula 1 at a concent...
|
|
WO/2024/097439A1 |
A method of treating X-linked juvenile retinoschisis (XLRS) in a human subject includes subretinally delivering to the human subject a therapeutically effective amount of an rAAV vector. The rAAV vector includes a nucleic acid sequence c...
|
|
WO/2024/095268A1 |
Methods for treating or reducing inflammation, in is in a site or an organ excluding the central nervous system of a subject in need thereof, by administering a pharmaceutical composition comprising the translocator protein ligand 2-C1-M...
|
|
WO/2024/097861A1 |
Provided herein are methods of ameliorating a disease or disorder associated with dysregulation of the alternative complement pathway by administering a Complement Factor B (CFB) specific inhibitor to a subject.
|
|
WO/2024/093907A1 |
Provided are a compound of formula (I) or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof. The compound of formula (I) is contained inside a nucleotide, or at a 5' end and/or a 3' end, and is used for improving the ...
|
|
WO/2024/095003A1 |
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts, N-oxides, solvates and prodrugs thereof: Formula (I) wherein Z, X, R1, R2, R4, R5, R6 and R7 are as defined in the specification, processes fo...
|
|
WO/2024/090941A1 |
The present invention relates to a composition for the prevention, amelioration or treatment of an anterior segment eye disease, the composition comprising a plant extract of the genus Aloe as an active ingredient. When the Aloe vera ext...
|
|
WO/2024/089691A1 |
The present disclosure relates to small molecule compound (SMC) modulators, compositions comprising the SMC modulators, uses thereof and methods for their use in modulating activity of CCR1 in a Muller cell and treating retinal disease.
|
|
WO/2024/089296A1 |
The present invention is directed to novel modulators of the Ca2+-signaling cascade, acting as potentiators of the P2RY2 purinergic receptor and of the inositol triphosphate receptors, ITPRs. The compounds are useful in the treatment of ...
|
|
WO/2024/091952A1 |
Disclosed herein are compositions comprising antioxidants and methods of use thereof.
|
|
WO/2024/090606A1 |
The present invention provides a method for treating posterior scleritis, comprising a first step of administering a steroid to a posterior scleritis patient through an intravenous injection, and a second step of orally administering a s...
|
|
WO/2024/091523A1 |
The present disclosure relates in some aspects to certain phenethylamine analogs, such as benzocyclobutene and benzocyclopentene analogs, including those of Formula (1). Also provided are methods of synthesizing the compounds, compositio...
|
|
WO/2024/088175A1 |
Disclosed in the present disclosure are a gRNA targeting VEGFA, a gene editing system, and the use thereof. The gRNA in the present disclosure comprises a guide sequence which has at least 80% sequence identity to any one of SEQ ID NOs: ...
|
|
WO/2024/090512A1 |
The present invention relates to novel crystals of KUS121 that are useful as a pharmaceutical, and a method for producing the same.
|
|
WO/2024/088110A1 |
Provided are a heterocyclic macrocyclic compound containing an indazole structure and used as a protein kinase inhibitor, and a preparation method therefor. The compound has the structure represented by general formula (I). Additionally ...
|
|
WO/2024/088364A1 |
The present disclosure relates to a pharmaceutical composition containing an isoquinolinone compound, and to a preparation method therefor. Specifically, the present disclosure provides a pharmaceutical composition containing 9,10-dimeth...
|
|
WO/2024/088156A1 |
The present invention relates to a novel use of recombinant human ocriplasmin in the preparation of a drug for treating and/or preventing a choroidal vascular disease.
|
|
WO/2024/091653A1 |
The present invention relates to methods of orally administering water soluble extracts of spearmint to subjects in a therapeutically effective amount to attenuate retinal cell damage and other neural cell damage outside the central nerv...
|
|
WO/2024/091789A1 |
Myopia progression is safely and effectively reduced by topical administration of a storage-stable low-dose formulation in which atropine is present at a concentration of 0.01%. Unexpectedly, such formulation was proven more effective to...
|
|
WO/2024/091659A1 |
The present invention provides for the treatment, prevention, and/or reduction of a risk of an ocular disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, by the use of a disclosed formulations.
|
|
WO/2024/088921A1 |
The invention is concerned with a method of predicting response to an IL-6 angatonist such as anti-IL-6 antibody by determing the concentration of IL-6 in human aqueous humor. The invention is also concerned with an IL-6 angatonist for u...
|
|
WO/2024/091014A1 |
The present invention relates to a pharmaceutical composition for preventing or treating hearing loss, comprising ammonium lactate as an active ingredient. Since it was confirmed that the number of normal sensory hair cells increased whe...
|
|
WO/2024/092086A1 |
The invention relates to regenerating corneal endothelium to treat vision loss in a subject in need thereof. The invention includes a lipid nanoparticle (LNP) capable of regenerating corneal endothelium in a subject in need thereof. The ...
|
|
WO/2024/092210A1 |
Provided herein are methods to treat fibrosis and/or inhibit angiogenesis.
|
|
WO/2024/085100A1 |
The present disclosure relates to a solid particle dispersed oily preparation. The present disclosure also provides a solid particle dispersed oily preparation suited to eyedrops or intraocular administration. The solid particle disperse...
|
|
WO/2024/086555A1 |
The present disclosure generally relates to methods of treating geographic atrophy (GA), reducing the growth rate of total GA lesion area, slowing the loss of visual acuity, and preventing or slowing development and/or progression of cho...
|
|
WO/2024/083956A1 |
The present invention relates to a formulation of josamycin or a related compound in a crosslinked poly- or oligosaccharide, and the use of this formulation in ophthalmic treatment of infection and fibrosis.
|
|
WO/2024/085081A1 |
Provided is an antibody that specifically binds to the extracellular domain of human LPA1 but does not specifically bind to the extracellular domain of human LPA2 or the extracellular domain of human LPA3. The antibody preferably has act...
|
